N euromodulation represents an exciting new approach that is being increasingly used as both acute and preventative treatment for migraine, providing a valid alternative option for patients for whom traditional drugs have failed, or for those who do not tolerate their side effects. This brief review aims at describing noninvasive neuromodulation techniques, which are currently the most used in clinical practice, specifically focusing on transcranial magnetic stimulation, vagus nerve stimulation and supraorbital nerve stimulation. Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given nal approval to the version to be published.
years. 1 The management of chronic or refractory migraine with traditional pharmacological approaches can often prove challenging and unsatisfactory. In recent years, migraine therapy has witnessed rapid advance of techniques that offer a valid alternative to the common preventive treatments, with generally limited and tolerable side effects.
Noninvasive neuromodulation approaches act through the transcutaneous stimulation of either cortical areas or peripheral nerves that are involved in pain. They allow to extend a treatment previously reserved to a select subgroup of patients also to sufferers experiencing less severe forms of migraine, who nonetheless desire avoiding the common side effects caused by medication.
Transcranial magnetic stimulation
Transcranial magnetic stimulation (TMS) is a noninvasive technique that was first discovered in 1985. 2 It is applied externally to the scalp and creates a fluctuating magnetic field capable of inducing an electrical current to the underlying cerebral cortex, which in turn has the effect of changing the firing pattern of neurons. TMS has been shown to disrupt the wave of cortical spreading depression (CSD), which is thought to be the experimental correlate of migraine aura. 3, 4 CSD may indeed induce head pain via cortico-thalamic circuits. 5 TMS has been used in a variety of research and clinical settings, including headache, mainly because of its safety and non-invasiveness. 6, 7 It can be delivered as one pulse or as trains of repeated stimulations; single-pulse TMS (sTMS) has been studied as a treatment for acute and prophylactic therapy in migraine, while fewer studies have evaluated the effect of repetitive TMS (rTMS).
A preliminary study using table-top sTMS device had shown good tolerability and efficacy in treating acute attacks in 42 migraine patients. 8 A more feasible, hand-held sTMS device was tested in a randomised controlled trial (RCT) involving 164 migraine with aura patients. 9 In this study, two TMS pulses separated by a 30-second interval were administered over the occipital cortex to treat a migraine with aura attack within one hour of symptom onset. TMS showed a 17% gain in pain-free rates at two hours with respect to the sham stimulation (39 vs. A similar observational study is currently ongoing in the US and is aimed at evaluating the efficacy of sTMS in migraine with or without aura (NCT02357381). An RCT testing the use of rTMS over the visual cortex in preventing chronic migraine is also ongoing (NCT02122744). Limitations to the use of sTMS come from the observation that the main study exploring its efficacy was exclusively directed to aura patients; as in all device trials, it is also difficult to exclude a certain degree of unblinding although this was very well balanced in this study. The second study, although directed to a broader population of migraine patients, was not a RCT.
Transcutaneous vagus nerve stimulation
Invasive vagus nerve stimulation (VNS) was initially used as a treatment for epilepsy 11 and depression; 12 interestingly, its effect on headache was first suggested by observing a reduction in the frequency of migraine attacks -and not seizures -in a patient who was implanted with a VNS device for epilepsy; 13 other preliminary reports further confirmed this result.
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The positive outcome of VNS on headache led to the development of a portable transcutaneous non-invasive device (GammaCore 21 Another open-label report on patients with episodic and chronic migraine showed an overall reduction of almost six headache days per month after a three-month nVNS preventive treatment. 22 A randomised sham-controlled study for episodic migraine prevention is currently ongoing (NCT02378844). Future trials to confirm these results are warranted, given that the studies treated relatively small numbers of patients and that the double-blind phase for the only available RCT showed a somewhat modest reduction in headache days.
Transcutaneous supraorbital nerve stimulation
The use of transcutaneous electrical current administered to cutaneous sensory or cranial nerves for the treatment of headache has been applied for many years, and reappeared in the modern literature as long as 30 years ago, 23 although its use has been limited because of conflicting results.
A novel technique based on the application of electrical current to the supraorbital nerve has recently been studied for migraine prevention in a randomised controlled trial. 24 This RCT tested the use of a supraorbital transcutaneous stimulator called the Cefaly ® device (Cefaly Technology, Nuneaton, UK), applied bilaterally for 20 minutes daily for three months to the supraorbital and supratrochlear nerves, in 67 migraine patients.
The treatment group showed a significant reduction in headache days, migraine attacks and use of abortive medications in respect to the sham group. Subsequently, a large survey was performed on 2,313 patients using the device, showing only minor adverse events and an overall high safety and satisfaction with treatment. 25 Pitfalls in the study include unblinding caused by paresthesias induced by the device, which are quite noticeable and uncomfortable, as well as a relatively small improvement measured in terms of number of headache days. In 2014, the FDA gave nonetheless approval for the use of Cefaly device in the prevention of migraine, and the device is also CE-marked in Europe.
Conclusions
Noninvasive neuromodulation is an exciting and useful method that is being increasingly recognised as a valid strategy for migraine management. It not only offers a safe and effective alternative to pharmacological treatments, but also provides interesting insights into the biology of migraine itself. Further RCTs need to be undertaken in the future, however, to confirm these promising results. q 
